Irina Cornaciu
Irina Cornaciu has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- José Antonio Márquez
European Molecular Biology Laboratory, EMBL Grenoble, 71 avenue des Martyrs, 9018 38042 Grenoble, France
2 shared publications - Andrea Pica
ALPX, 71 Avenue des Martyrs, 38000 Grenoble, France
1 shared publication - Andreas L. Marzinzik
Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland
1 shared publication - Anne-Sophie Banneville
Univ. Grenoble Alpes, CNRS, CEA, IBS, F-38000 Grenoble
1 shared publication - Anne-Sophie Humm
European Molecular Biology Laboratory (EMBL) Grenoble
1 shared publication - Antonello Merlino
Department of Chemical Sciences, University of Naples Federico II
1 shared publication
Latest Publications
- Open Access
- 16 January 2026
- Published by Springer Nature in Communications Chemistry
- Vol. 9 (1)
First crystal structure of an adduct formed upon reaction of a vanadium compound with human serum transferrin
The interaction of vanadium compounds of pharmaceutical interest with metal-transport proteins like human serum transferrin (hTF) is poorly understood. Direct structural evidence identifying vanadium binding sites on hTF is still lacking. Here, the X-ray structure of the adduct formed when the potential drug [VIVO(acac)2], with acac = acetylacetonato, reacts with human serum transferrin with Fe3+ bound at the C-lobe only (FeC-hTF) has been solved and compared with new structures of FeC-hTF used as controls. Structural analysis revealed the presence of a [VV2O6]2– anion that can be described as a divanadate(V) anion, [VV2O7]4–, that has one oxygen replaced by the phenolate oxygen of Tyr188. The two vanadium centers adopt tetrahedral geometry, consistent with VV behavior. The binding does not alter the overall conformation of FeC-hTF that retains the open conformation of the N-lobe and the closed conformation of the C-lobe, remaining able to be recognized by the transferrin receptor.
- 16 January 2026
- Published by Springer Nature in Communications Chemistry
- Vol. 9 (1)
Open AccessFirst crystal structure of an adduct formed upon reaction of a vanadium compound with human serum transferrin
The interaction of vanadium compounds of pharmaceutical interest with metal-transport proteins like human serum transferrin (hTF) is poorly understood. Direct structural evidence identifying vanadium binding sites on hTF is still lacking. Here, the X-ray structure of the adduct formed when the potential drug [VIVO(acac)2], with acac = acetylacetonato, reacts with human serum transferrin with Fe3+ bound at the C-lobe only (FeC-hTF) has been solved and compared with new structures of FeC-hTF used as controls. Structural analysis revealed the presence of a [VV2O6]2– anion that can be described as a divanadate(V) anion, [VV2O7]4–, that has one oxygen replaced by the phenolate oxygen of Tyr188. The two vanadium centers adopt tetrahedral geometry, consistent with VV behavior. The binding does not alter the overall conformation of FeC-hTF that retains the open conformation of the N-lobe and the closed conformation of the C-lobe, remaining able to be recognized by the transferrin receptor.
- Open Access
Plasticity of the binding pocket in peptide transporters underpins promiscuous substrate recognition
Summary: Proton-coupled oligopeptide transporters (POTs) are promiscuous transporters of the Major Facilitator Superfamily, that constitute the main route of entry for a wide range of dietary peptides and orally administrated peptidomimetic drugs. Given their clinical and pathophysiological relevance, several bacterial and mammalian POT homologs have been extensively studied on a structural and molecular level. However, the molecular basis of recognition and transport of the wide range of peptide substrates has remained elusive. Here we present 14 X-ray structures of the bacterial POT DtpB in complex with chemically diverse di- and tripeptides, providing novel insights into the plasticity of the conserved central binding cavity. We analyzed binding affinities for more than 80 peptides and monitored uptake by a fluorescence-based transport assay. To probe if all natural 8400 di- and tripeptides can bind to DtpB, we employed state-of-the-art molecular docking and machine learning and conclude that peptides of a specific subset with compact hydrophobic residues are the best DtpB binders.
Open AccessPlasticity of the binding pocket in peptide transporters underpins promiscuous substrate recognition
Summary: Proton-coupled oligopeptide transporters (POTs) are promiscuous transporters of the Major Facilitator Superfamily, that constitute the main route of entry for a wide range of dietary peptides and orally administrated peptidomimetic drugs. Given their clinical and pathophysiological relevance, several bacterial and mammalian POT homologs have been extensively studied on a structural and molecular level. However, the molecular basis of recognition and transport of the wide range of peptide substrates has remained elusive. Here we present 14 X-ray structures of the bacterial POT DtpB in complex with chemically diverse di- and tripeptides, providing novel insights into the plasticity of the conserved central binding cavity. We analyzed binding affinities for more than 80 peptides and monitored uptake by a fluorescence-based transport assay. To probe if all natural 8400 di- and tripeptides can bind to DtpB, we employed state-of-the-art molecular docking and machine learning and conclude that peptides of a specific subset with compact hydrophobic residues are the best DtpB binders.
- Open Access
- 14 June 2020
- Published by Wiley in ChemBioChem
- Vol. 21 (21) , 3096-3111
Fragment‐Based Discovery of Non‐bisphosphonate Binders of Trypanosoma brucei Farnesyl Pyrophosphate Synthase
Trypanosoma brucei is the causative agent of human African trypanosomiasis (HAT). Nitrogen‐containing bisphosphonates, a current treatment for bone diseases, have been shown to block the growth of the T. brucei parasites by inhibiting farnesyl pyrophosphate synthase (FPPS); however, due to their poor pharmacokinetic properties, they are not well suited for antiparasitic therapy. Recently, an allosteric binding pocket was discovered on human FPPS, but its existence on trypanosomal FPPS was unclear. We applied NMR and X‐ray fragment screening to T. brucei FPPS and report herein on four fragments bound to this previously unknown allosteric site. Surprisingly, non‐bisphosphonate active‐site binders were also identified. Moreover, fragment screening revealed a number of additional binding sites. In an early structure–activity relationship (SAR) study, an analogue of an active‐site binder was unexpectedly shown to bind to the allosteric site. Overlaying identified fragment binders of a parallel T. cruzi FPPS fragment screen with the T. brucei FPPS structure, and medicinal chemistry optimisation based on two binders revealed another example of fragment “pocket hopping”. The discovery of binders with new chemotypes sets the framework for developing advanced compounds with pharmacokinetic properties suitable for the treatment of parasitic infections by inhibition of FPPS in T. brucei parasites.
- 14 June 2020
- Published by Wiley in ChemBioChem
- Vol. 21 (21) , 3096-3111
Open AccessFragment‐Based Discovery of Non‐bisphosphonate Binders of Trypanosoma brucei Farnesyl Pyrophosphate Synthase
Trypanosoma brucei is the causative agent of human African trypanosomiasis (HAT). Nitrogen‐containing bisphosphonates, a current treatment for bone diseases, have been shown to block the growth of the T. brucei parasites by inhibiting farnesyl pyrophosphate synthase (FPPS); however, due to their poor pharmacokinetic properties, they are not well suited for antiparasitic therapy. Recently, an allosteric binding pocket was discovered on human FPPS, but its existence on trypanosomal FPPS was unclear. We applied NMR and X‐ray fragment screening to T. brucei FPPS and report herein on four fragments bound to this previously unknown allosteric site. Surprisingly, non‐bisphosphonate active‐site binders were also identified. Moreover, fragment screening revealed a number of additional binding sites. In an early structure–activity relationship (SAR) study, an analogue of an active‐site binder was unexpectedly shown to bind to the allosteric site. Overlaying identified fragment binders of a parallel T. cruzi FPPS fragment screen with the T. brucei FPPS structure, and medicinal chemistry optimisation based on two binders revealed another example of fragment “pocket hopping”. The discovery of binders with new chemotypes sets the framework for developing advanced compounds with pharmacokinetic properties suitable for the treatment of parasitic infections by inhibition of FPPS in T. brucei parasites.